New Amsterdam Partners’s Globus Medical GMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-20,297
Closed -$878K 117
2018
Q4
$878K Buy
+20,297
New +$1.01M 0.29% 81
2018
Q3
Sell
-70,363
Closed -$3.55M 121
2018
Q2
$3.55M Buy
70,363
+762
+1% +$39.7K 0.84% 46
2018
Q1
$3.47M Sell
69,601
-83,305
-54% -$3.92M 0.76% 48
2017
Q4
$6.28M Buy
152,906
+425
+0.3% +$14.9K 1.26% 34
2017
Q3
$4.53M Sell
152,481
-9,238
-6% -$282K 0.95% 47
2017
Q2
$5.36M Sell
161,719
-3,550
-2% -$112K 1.14% 36
2017
Q1
$4.89M Buy
165,269
+37,071
+29% +$1.01M 1.16% 38
2016
Q4
$3.18M Sell
128,198
-26,164
-17% -$595K 0.72% 58
2016
Q3
$3.48M Sell
154,362
-41,511
-21% -$976K 0.8% 57
2016
Q2
$4.67M Sell
195,873
-700,275
-78% -$16.8M 1.13% 37
2016
Q1
$21.3M Sell
896,148
-10,382
-1% -$254K 2.23% 8
2015
Q4
$25.2M Buy
906,530
+275,857
+44% +$6.93M 2.6% 3
2015
Q3
$13M Sell
630,673
-111,705
-15% -$2.83M 1.32% 35
2015
Q2
$19.1M Sell
742,378
-3,882
-0.5% -$98.3K 1.64% 34
2015
Q1
$18.8M Buy
746,260
+152,160
+26% +$3.71M 1.52% 30
2014
Q4
$14.1M Buy
+594,100
New +$13.2M 1.23% 35

Other funds holding GMED

New Amsterdam Partners's GMED Position: Q1 2019 in Review

New Amsterdam Partners sold out of Globus Medical (GMED) in Q1 2019, closing a stake of 20,297 shares — an estimated $878K sold.

New Amsterdam Partners first reported a position in GMED in Q4 2014 and held it in 16 quarters. The position peaked at $25.2M in Q4 2015. 269 funds tracked by Wall St. Rank hold GMED as of Q1 2019.

  • New Amsterdam Partners reported no remaining Globus Medical position as of Q1 2019 after selling out during the quarter.
  • New Amsterdam Partners sold 20,297 Globus Medical shares in Q1 2019, an estimated $878K.
  • New Amsterdam Partners first reported a position in Globus Medical in Q4 2014 and held it in 16 quarters.
  • New Amsterdam Partners's Globus Medical position peaked at $25.2M in Q4 2015.
  • 269 funds tracked by Wall St. Rank held Globus Medical as of Q1 2019.

Based on New Amsterdam Partners's 13F filing for Q1 2019, filed 2 May 2019.